Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate

Antiviral Research

Volumn 61, Issue 2, 2004, Pages 101-109

  Jenssen, Håvard ^a,b   Andersen, Jeanette Hammer ^a   Uhlin Hansen, Lars ^a   Gutteberg, Tore Jarl ^a   Rekdal, Øystein ^b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Antiviral activity; Heparan sulfate; Herpes simplex virus; Lactoferricin; Structure activity relation

Indexed keywords

AMINO ACID; ANTI HERPES SIMPLEX VIRUS AGENT; ANTIVIRUS AGENT; CHONDROITIN SULFATE; HEPARAN SULFATE; LACTOFERRICIN; UNCLASSIFIED DRUG; VIRUS RECEPTOR;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HYDROPHOBICITY; LIPOPHILICITY; MOLECULAR SIZE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

BOVINAE; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

EID: 0344304749     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2003.09.001     Document Type: Article

References (42)

1. Andersen J.H., Osbakk S.A., Vorland L.H., Traavik T., Gutteberg T.J. Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res. 51:2001;141-149.
2. Andersen, J.H., Jenssen, H., Gutteberg, T.J., 2002. Lactoferricin inhibits the entry of HSV-1. In: 28th International Herpes Workshop, Cairns, Australia.
3. Andersen J.H., Jenssen H., Gutteberg T.J. Lactoferrin and lactoferricin inhibit herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res. 58:2003;209-215.
4. Banfield B.W., Leduc Y., Esford L., Visalli R.J., Brandt C.R., Tufaro F. Evidence for an interaction of herpes simplex virus with chondroitin sulfate proteoglycans during infection. Virology. 208:1995;531-539.
5. Bellamy W., Takase M., Wakabayashi H., Kawase K., Tomita M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J. Appl. Bacteriol. 73:1992;472-479.
6. Cardin A.D., Weintraub H.J. Molecular modeling of protein- glycosaminoglycan interactions. Arteriosclerosis. 9:1989;21-32.
7. Casu B., Choay J., Ferro D.R., Gatti G., Jacquinet J.C., Petitou M., Provasoli A., Ragazzi M., Sinay P., Torri G. Controversial glycosaminoglycan conformations. Nature. 322:1986;215-216.
8. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:1984;27-55.
9. El Yazidi-Belkoura I., Legrand D., Nuijens J., Slomianny M.C., van Berkel P., Spik G. The binding of lactoferrin to glycosaminoglycans on enterocyte-like HT29-18-C1 cells is mediated through basic residues located in the N-terminus. Biochim. Biophys. Acta. 1568:2001;197-204.
10. Hammer, J., Haaheim, H., Gutteberg, T.J., 2000. Bovine lactoferrin is more efficient than bovine lactoferricin in inhibiting HSV-I/II replication in vitro. In: Shimazaki, K. (Ed.), Lactoferrin: Structure, Functions and Application. Elsevier Science, Amsterdam, pp. 239-243.
11. Harmsen M.C., Swart P.J., de Béthune M.P., Pauwels R., De Clercq E., Thé T.H., Meijer D.K. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J. Infect. Dis. 172:1995;380-388.
12. Haug B.E., Svendsen J.S. The role of tryptophan in the antibacterial activity of a 15-residue bovine lactoferricin peptide. J. Pept. Sci. 7:2001;190-196.
13. Hutton R.D., Ewert D.L., French G.R. Differentiation of types 1 and 2 herpes simplex virus by plaque inhibition with sulfated polyanions. Proc. Soc. Exp. Biol. Med. 142:1973;27-29.
14. Ikai A. Thermostability and aliphatic index of globular proteins. J. Biochem. (Tokyo). 88:1980;1895-1898.
15. Ji Z.S., Mahley R.W. Lactoferrin binding to heparan sulfate proteoglycans and the LDL receptor-related protein. Further evidence supporting the importance of direct binding of remnant lipoproteins to HSPG. Arterioscler. Thromb. 14:1994;2025-2031.
16. Kuwata H., Yip T.T., Yamauchi K., Teraguchi S., Hayasawa H., Tomita M., Hutchens T.W. The survival of ingested lactoferrin in the gastrointestinal tract of adult mice. Biochem. J. 334:1998;321-323.
17. Kyte J., Doolittle R.F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157:1982;105-132.
18. Langeland N., Moore L.J., Holmsen H., Haarr L. Interaction of polylysine with the cellular receptor for herpes simplex virus type 1. J. Gen. Virol. 69:1988;1137-1145.
19. Laquerre S., Argnani R., Anderson D.B., Zucchini S., Manservigi R., Glorioso J.C. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J. Virol. 72:1998;6119-6130.
20. Lee, K.K., Black, J.A., Hodges, R.S., 1989. Air oxidation of peptides and separation of their reduced and intrachain disulfide bridged forms by reversed-phase high performance liquid chromatography (RPC). In: 11th American Peptide Symposium, San Diego, CA.
21. Lindahl U., Lidholt K., Spillmann D., Kjellen L. More to "heparin" than anticoagulation. Thromb. Res. 75:1994;1-32.
22. Mann D.M., Romm E., Migliorini M. Delineation of the glycosaminoglycan- binding site in the human inflammatory response protein lactoferrin. J. Biol. Chem. 269:1994;23661-23667.
23. Marchetti M., Longhi C., Conte M.P., Pisani S., Valenti P., Seganti L. Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells. Antiviral Res. 29:1996;221-231.
24. Mardberg K., Trybala E., Tufaro F., Bergstrom T. Herpes simplex virus type 1 glycoprotein C is necessary for efficient infection of chondroitin sulfate-expressing gro2C cells. J. Gen. Virol. 83:2002;291-300.
25. Masson P.L., Heremans J.F., Dive C. Studies of the proteins of secretions from two villous tumours of the rectum. Gastroenterologia. 105:1966;270-282.
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
27. Omata Y., Satake M., Maeda R., Saito A., Shimazaki K., Yamauchi K., Uzuka Y., Tanabe S., Sarashina T., Mikami T. Reduction of the infectivity of Toxoplasma gondii and Eimeria stiedai sporozoites by treatment with bovine lactoferricin. J. Vet. Med. Sci. 63:2001;187-190.
28. Qie L., Marcellino D., Herold B.C. Herpes simplex virus entry is associated with tyrosine phosphorylation of cellular proteins. Virology. 256:1999;220-227.
29. Rekdal O., Andersen J., Vorland L.H., Svendsen J.S. Construction and synthesis of lactoferricin derivatives with enhanced antibacterial activity. J. Pept. Sci. 5:1999;32-45.
30. Reyes M., Shaik N.S., Graber J.M., Nisenbaum R., Wetherall N.T., Fukuda K., Reeves W.C. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch. Intern. Med. 163:2003;76-80.
31. Sanderson P.N., Huckerby T.N., Nieduszynski I.A. Conformational equilibria of alpha-L-iduronate residues in disaccharides derived from heparin. Biochem. J. 243:1987;175-181.
32. Stringer S.E., Gallagher J.T. Heparan sulphate. Int. J. Biochem. Cell. Biol. 29:1997;709-714.
33. Strom M.B., Rekdal O., Svendsen J.S. Antibacterial activity of 15-residue lactoferricin derivatives. J. Pept. Res. 56:2000;265-274.
34. Strom M.B., Rekdal O., Svendsen J.S. The effects of charge and lipophilicity on the antibacterial activity of undecapeptides derived from bovine lactoferricin. J. Pept. Sci. 8:2002;36-43.
35. Tal-Singer R., Peng C., Ponce De Leon L., Abrams W.R., Banfield B.W., Tufaro F., Cohen G.H., Eisenberg R.J. Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J. Virol. 69:1995;4471-4483.
36. Trybala E., Liljeqvist J.A., Svennerholm B., Bergstrom T. Herpes simplex virus types 1 and 2 differ in their interaction with heparan sulfate. J. Virol. 74:2000;9106-9114.
37. Ueta E., Tanida T., Osaki T. A novel bovine lactoferrin peptide, FKCRRWQWRM, suppresses Candida cell growth and activates neutrophils. J. Pept. Res. 57:2001;240-249.
38. Weinberg E.D. Human lactoferrin: a novel therapeutic with broad spectrum potential. J. Pharm. Pharmacol. 53:2001;1303-1310.
39. Whitley R.J., Kimberlin D.W., Roizman B. Herpes simplex viruses. Clin. Infect. Dis. 26:1998;541-553.
40. Wu H.F., Monroe D.M., Church F.C. Characterization of the glycosaminoglycan-binding region of lactoferrin. Arch. Biochem. Biophys. 317:1995;85-92.
41. WuDunn D., Spear P.G. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J. Virol. 63:1989;52-58.
42. Yoo Y.C., Watanabe S., Watanabe R., Hata K., Shimazaki K., Azuma I. Bovine lactoferrin and lactoferricin inhibit tumor metastasis in mice. Adv. Exp. Med. Biol. 443:1998;285-291.